Clinical trials: Hematological Disease
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
This is a first-in-human trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor effects of GIC-102 in patients with advanced solid tumors, relapsed/refractory non-hodgkin lymphoma, and…
- Conditions
- Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma
- Trial name
- NCT05880043
- Testing
- GIC-102
- Where
- 4 sites in South Korea
- Volunteers
- 50 people
- Sponsor
- GI Cell, Inc.
Leukemia, Myeloid, Acute
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
This is an open-label, dose-escalating trial to evaluate the MTD and/or dose to be used for further development by evaluation of DLT in course 1 and the safety of volasertib when added to standard intensive salvage chemotherapy…
- Trial name
- NCT02722135
- Testing
- Volasertib
- Where
- Belgium
- Sponsor
- Boehringer Ingelheim
Acute Myeloid Leukemia
A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
The purpose of this study is to determine the bioequivalence of (cytarabine: daunorubicin) liposome for injection and Vyxeos in elderly acute myeloid leukemia (AML) subjects.
- Trial name
- NCT05801835
- Testing
- (cytarabine: daunorubicin) liposome for injection, Vyxeos
- Where
- China
- Volunteers
- 36 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Relapsed or Refractory Multiple Myeloma, Hematological Malignancy
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Trial name
- NCT04684108
- Testing
- SG301
- Where
- 14 sites in China
- Volunteers
- 61 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Immune Thrombocytopenia
Biologic Characterization of Patients With ITP
This is a no-profit, multicenter, biological, non-pharmacologic study aimed to characterize from a biological point of view previously untreated primary ITP patients.
- Trial name
- NCT05694325
- Testing
- peripheral blood and bone marrow withdrawal
- Where
- 5 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work
This study investigates the usefulness of the Self Care at Work Handbook in order to generate an improved version. Information from this study may help researchers identify potential factors associated with perception and…
- Trial name
- NCT05038384
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Hemophilia A
Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity
Hemophilia A is a rare X chromosome-linked recessive bleeding disorder that concerns one individual in 5000. In its severe form, hemophilia A is a life-threatening, crippling hemorrhagic disease.
- Trial name
- SOLUCLOT (NCT02911233)
- Testing
- Thromboelastograpgy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Caen
Paroxysmal Nocturnal Hemoglobinuria, PNH
Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
How does long term treatment with Soliris affect HAHA in PNH patients?
- Trial name
- NCT01412047
- Where
- 14 sites in United States, Australia and 8 more
- Volunteers
- 75 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Sickle Cell Disease
Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients
Symptomatic sickle cell disease is worldwide the most frequent cause for hereditary hemolytic anemia with recurrent pain crisis.
- Trial name
- MemSID (NCT02615847)
- Testing
- Memantinhydrochlorid
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- University of Zurich
Multiple Myeloma
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
To compare the efficacy of oral CC-5013 in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for subjects with relapsed or refractory multiple myeloma."
- Trial name
- NCT00424047
- Testing
- CC-5013 plus dexamethasone
- Where
- 69 sites in Australia, Austria and 13 more
- Volunteers
- 351 people
- Sponsor
- Celgene
Covid19, COVID-19 Respiratory Infection
Standardized Olive Leaf Capsules; as a Co-therapy in the Treatment of COVID-19 Patients
Starting from December 2019, novel coronavirus disease 2019 (COVID-19) pandemic has caused a tremendous economic loss and unprecedented health crisis across the globe.
- Conditions
- Covid19, COVID-19 Respiratory Infection, Symptoms and Signs, COVID-19 Acute Bronchitis
- Trial name
- NCT04873349
- Testing
- Nusapure standardized olive leaves capsule, 750 mg (50% oleuropein)
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Shimaa M. Abdelgawad
Leukaemia, Lymphocytic, Chronic
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.
- Trial name
- NCT00349349
- Testing
- ofatumumab
- Volunteers
- 223 people
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia
ITP Registry and Accompanying Biospecimen Collection
The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.
- Trial name
- ITP-Registry (NCT05152238)
- Where
- 64 sites in Germany
- Volunteers
- 1,100 people
- Sponsor
- Jena University Hospital
Immune Thrombocytopenia, Treatment
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not…
- Trial name
- NCT07362238
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Brain and Central Nervous System Tumors, Leukemia
Metabolic Syndrome in Childhood Cancer Survivors
RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood cancer may help doctors learn more about the disease.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Metabolic Syndrome
- Trial name
- NCT00920738
- Testing
- metabolic assessment, questionnaire administration
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Acute Myeloid Leukemia, Leukemia, Myeloid
Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid Leukemia
This study will explore how malnutrition (poor nutrition/diet) and sarcopenia (a condition that causes a loss of muscle and bone mass) affects study participants over the age of 60 with acute myeloid leukemia (AML) who will…
- Trial name
- NCT05458258
- Testing
- Bioelectrical Impedence Analysis Device, 6 Minute Walk Test, Computed Tomography Scans to Measure Skeletal Muscular Index
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- University of Chicago
Thrombotic Thrombocytopenic Purpura, Acquired
Daratumumab in Immune-mediated Thrombotic Thrombocytopenic Purpura
Data about efficacy and safety of daratumumab in iTTP refractory or intolerant to standard immunosuppressive treatments are scarce.
- Trial name
- DarTTP (NCT07513948)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Multiple Myeloma
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM).
- Trial name
- TACTAM (NCT02291848)
- Testing
- TAA-specific CTLs, TAA-specific CTLs- fixed dose
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Baylor College of Medicine
Acute Myeloid Leukemia, Adult, Cardiotoxicity
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of…
- Conditions
- Acute Myeloid Leukemia, Adult, Cardiotoxicity, Endothelial Dysfunction
- Trial name
- NCT05703126
- Testing
- History taking, Anthropometry, Complete blood count
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Samara State Medical University
Acute Myeloid Leukemia, Cachexia
Investigation of the Gut Microbiota in Patients With Acute Myeloid Leukemia
This cohort study aims to investigate the composition and activity of the gut microbiota of patients newly diagnosed for acute myeloid leukemia (AML), in relationship with their food habits and cachectic hallmarks.
- Trial name
- MicroAML (NCT03881826)
- Testing
- collection of clinical data and biological samples
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Université Catholique de Louvain
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.